The grades of 6 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This is a strong week for Ophthotech Corp. (OPHT). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of OPHT stock.
Vanda Pharmaceuticals Inc. (VNDA) shows solid improvement this week. The company’s rating rises from a C to a B. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VNDA stock.
This week, CoLucid Pharmaceuticals, Inc.’s (CLCD) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of CLCD stock.
Trevena, Inc. (TRVN) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of TRVN stock.
Vital Therapies, Inc. (VTL) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of VTL stock.
Nymox Pharmaceutical Corp (NYMX) boosts its rating from a C to a B this week. Nymox Pharmaceutical Corp is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. For more information, get Portfolio Grader’s complete analysis of NYMX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
